OBJECTIVES: Data about the burden of JIA are necessary to allocate health care resources. METHODS: Records were examined for 6 months retrospectively. Burden of JIA in Russia was gotten by summarizing direct and indirect medical costs of all patients with JIA. The total number of JIA patients and annualized costs were calculated based on extrapolation method.   RESULTS: Data on 405 patients were obtained. Group with biologics included 124 patients(30.6%), without biologics – 269(66.4%), data about 9(3%) persons were absent. Among 6 biologics used in Russia for JIA treatment (Abatacept, Adalimumab, Etanercept, Infliximab, Rituximab and Tocilizumab), costs of biologics and total costs per patient were the smallest in case of Etanercept – 5,131 USD and 6,967 USD and the biggest with Rituximab - 19,530 USD and 21,944 USD. One-year  direct costs per patient with biologics were 36,065 USD. One-year direct costs per patient without biologics was 3149 USD. Average one-year indirect costs were the same for patients with and without biologics - 1442 USD. Total number of patients with JIA in 2010 was 18,626 people, only 930(5%) (data of National Center for Child Health of Russian Academy of Medical Sciences, Moscow, Russia) received biologics. One-year direct costs of all patients with JIA - 89,491,976 USD; indirect costs - 27,491,976 USD; the burden of JIA -116,754,031 USD. CONCLUSIONS: In 2010 total number of patients with JIA in Russia was estimates as 18,626 people; burden of JIA was 116,754,031 USD.